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The objective of the present study was to develop 2-hydroxypropyl
methacrylate-co-polyethylene methacrylate [p(HPMA-co-PEG–MEMA)] hydrogels
that are able to efficiently entrap doxorubicin for the application of loco-regional
control of the cancer disease. Systemic chemotherapy provides low clinical benefit
while localized chemotherapy might provide a therapeutic advantage. In this study,
effects of hydrogel properties such as PEG chains length, cross-linking density,
biocompatibility, drug loading efficiency, and drug release kinetics were evaluated
in vitro for targeted and controlled drug delivery. In addition, the characterization of
the hydrogel formulations was conducted with swelling experiments, permeability
tests, Fourier transform infrared, SEM, and contact angle studies. In these drug-
hydrogel systems, doxorubicin contains amine group that can be expected a strong
Lewis acid–base interaction between drug and polar groups of PEG chains, thus the
drug was released in a timely fashion with an electrostatic interaction mechanism. It
was observed that doxorubicin release from the hydrogel formulations decreased when
the density of cross-linking, and drug/polymer ratio were increased while an increase
in the PEG chains length of the macro-monomer (i.e. PEG–MEMA) in the hydrogel
system was associated with an increase in water content and doxorubicin release. The
biocompatibility of the hydrogel formulations has been investigated using two
measures: cytotoxicity test (using lactate dehydrogenase assay) and major serum pro-
teins adsorption studies. Antitumor activity of the released doxorubicin was assessed
using a human SNU398 human hepatocellular carcinoma cell line. It was observed that
doxorubicin released from all of our hydrogel formulations which remained
biologically active and had the capability to kill the tested cancer cells.
Keywords: hydrogels; biocompatibility; drug delivery; doxorubicin; hepatocellular
carcinoma cell; biomedical applications
1. Introduction
Selective and targeted delivery of drugs is a major challenge for effective therapy of
many diseases. An ideal drug delivery system should be inert, biocompatible,
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mechanically strong, comfortable for the patient, capable of achieving a high drug
loading for the required blood levels, immune to accidental release, simple to apply,
and easy to fabricate.[1–5] Hydrogels are hydrophilic polymer networks which can
retain large amount of water, and expand from 10 to 1000% of their dry weight. The
networks change its volume by imbibing or draining water in response to environmen-
tal factors such as temperature, pH, light, or ionic strength.[4–8] Entrapment of
anticancer drugs to hydrogels is a promising approach to improve the efficacy and
reduce the side effects of these drugs.[8,9] Numerous hydrogel-drug formulations have
been developed for controlled release of active ingredients. Among them,
poly(2-hydroxypropyl methacrylate), p(HPMA), and its copolymer hydrogels have
found extensive applications in the biomedical field mainly because of their good
chemical stability and high biocompatibility.[10–14] Hydrogels containing PEG are
interesting biomaterials because they exhibit low degrees of protein adsorption and cell
adhesion, low toxicity, and good water soloublity.[15–20]
Doxorubicin is a chemotherapeutic agent commonly used in the treatment of a wide
range of different cancer types. The use of doxorubicin and its derivatives causes
dilated cardiomyopathy and congestive heart failure due to the accumulation of the
drug and results in doxorubicin-induced cardiotoxicity.[21,22] In addition, doxorubicin
has been used as a model drug in many drug release studies, and different hydrogel for-
mulations have been used for developing these drug release systems.[23,24] Electro-
static interactions between doxorubicin and hydrogels were previously reported for
controlled release of the drug.[25,26] Hybrid hydrogel is another approach that has
been used in controlled release studies.[27] For example, chitosan-gold particles or
chitosan-polyvinyl alcohol conjugates were reported as drug delivery systems for con-
trolled doxorubicin release with low toxicity to healthy tissues.[28,29]
In this study, hydrogel networks consisting of poly(2-hydroxypropyl methacrylate,
and polyethylene glycole-methylether methacrylate) with different compositions and
doxorubicin loading were prepared by UV-induced polymerization for the construction
of a controlled drug release system. The hydrogel films were characterized by Fourier
transform infrared (FTIR), SEM, swelling ratios, permeability, and contact angle stud-
ies. The effects of the PEG chain length of the macro-monomer (i.e. PEG–MEMA-1-3
ratio), cross-linker density, and the amount of loaded drug on the doxorubicin release
were studied in a continuous drug release system. The kinetics of drug release from
p(HPMA/PEG–MEMA) formulations were also analyzed. The major blood protein
interactions with the hydrogel formulations were also determined. Finally, in vitro anti-
tumor efficiency of the five different doxorubicin loaded p(HPMA/PEG-950-300)-X1
and p(HPMA/PEG-300)-X1-X3 formulations were evaluated using SNU398 human
hepatocellular carcinoma cell line. The results were compared with the antitumor effects
of the drug free counterparts of these formulations under the same conditions. To this
end, the aim of this study was to determine optimum PEG chain length and the amount
of cross-linker.
2. Materials and methods
2.1. Materials
2-Hydroxypropyl methacrylate (HPMA), polyethylene glycole-methylether methacrylate
(PEG–MEMA) with three different average Mn 300, 475, and 975 (i.e. PEG chains
length), N,N-methylene bisacrylamide (BisAA), tetramethylene diamine (TEMED), and
ammonium persulphate (APS) were obtained from Sigma-Aldrich chemicals GmbH
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(Germany). Human serum albumin (HSA), human immuno-globulins (Igs), and
fibrinogen were supplied from Sigma-Aldrich and used as received. Doxorubicin was
supplied by Fresenius Ltd., UK and used as received. Its chemical formula is shown in
Figure 1(a). All other chemicals were of reagent grade and were purchased from Merck
AG (Darmstadt, Germany). All other chemicals were analytical-grade and were
purchased from Merck AG (Darmstadt, Germany).
2.2. Cell culture
SNU398 Human hepatocellular carcinoma cell line was cultured in RPMI medium
(LONZA) supplemented with 10.0% fetal bovine serum, 1.0% non-essential amino
acids, and 1.0% Penicillin/Streptomycin antibiotic at 37 °C in 5.0% CO2 incubator.
2.3. Preparation of the p(HPMA/PEG–MEMA) hydrogel film formulations
The p(HPMA/PEG–MEMA) hydrogel film formulations were prepared using
UV-induced polymerization process. The representative chemical structure of the
copolymer film is presented in Figure 1(b). To test the effects of PEG chains length on
the drug entrapment efficiency and release rates, PEG–MEMA macro-monomers with
three different averages Mn (i.e. 950, 475, and 300) were used in the initial polymeriza-
tion mixture, and here after the formulations were referred to p(HPMA/PEG-950)X1,
p(HPMA/PEG-475)X1, and p(HPMA/PEG-300)X1, respectively. The monomer
(2-hydroxypropyl methacrylate; 0.75 mL), macro-monomer (polyethylene glycole-meth-
ylether methacrylate, 0.75 mL), cross-linker (i.e. N,N-methylene-bisacrylamide; 1.0 mg,
it was donated by X), amonium persulphate (5.0 mg), TEMED (10 μL from 10% solu-
tion w/v), and absolute ethanol (0.5 mL) were transferred in phosphate buffer (1.0 mL,
50 mM, pH 7.0) (Table 1). To check the effects of the cross-linker density on the film
properties and drug release efficiency in the initial polymerization mixture, the amount
of added BisAA was varied between 1.0 and 3.0 mg (or 6.5 and 19.2 μmol), and the
same amount macro-monomer PEG–MEMA-300 was used as described above. Here
Figure 1. (a) Chemical formula of doxorubicin; (b) Chemistry of p(HPMA/PEG–MEMA)
hydrogels.
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after, the formulations were referred as p(HPMA/PEG-300)X1 p(HPMA/PEG-300)X2
p(HPMA/PEG-300)X3. These resulting mixtures were equilibrated at 4 °C for 30 min
in a thermostatic water bath. Each polymerization mixture was transferred in a flat glass
mold (internal diameter: 6.5 cm). After sealing, a nitrogen atmosphere was created by
purging nitrogen gas for 5 min. It was then exposed to UV radiation (TUW series, Phi-
lips; UV-C, 254-nm short wave, 24W, Ankara, Turkey) at 4 °C for 30 min. The
obtained hydrogel films were cut into disks by means of a perforator (0.5 cm in diame-
ter and about 600 μm in thickness), and stored at 4 °C in the same buffer until use. For
the preparation of drug-loaded formulations, doxorubicin in two different concentra-
tions, 0.5 and 1.0 mg/mL, were added to the polymerization mixture (Table 1).
2.4. Characterization studies of the hydrogel films
The densities of the five different p(HPMA/PEG-950-300)X1, and p(HPMA/PEG-300)
X1-X3, formulations were determined by Gay-Lussac pycnometer (Dahlewitz,
Germany), and n-decane was chosen as the inert liquid, which is a non-solvent for the
hydrogel. The thickness of the hydrogel films was estimated by a micrometer thickness
gage. The morphology of hydrogel films and its drug-loaded counterpart were
investigated by a JEOL (Tokyo, Japan) model JSM 5600 scanning electron microscope.
The dried polymer films were mounted on the base plate and then coated with gold in
vacuum. The morphology and surface structure of the films were obtained at the
required magnification at room temperature. FTIR spectra of the p(HPMA/PEG-300)X1
films were obtained by an FTIR spectrophotometer (FTIR 8000 series, Shimadzu,
Tokyo, Japan). The dry sample (ca. 0.01 g) was mixed with KBr (0.1 g) and pressed
into tablet form.
2.5. Determination of volume fraction of water in hydrogels
The water contents of the p(HPMA/PEG-950-300)X1, and p(HPMA/PEG-300)X1-X3
hydrogels were determined by swelling measurements at 37 °C. The samples (0.1 g)
were first immersed in physiological phosphate buffer solution (PBS) pH 7.4, 50 mM,
containing 0.85% NaCl. The immersion time was 24 h. The films were removed from
PBS and their wet weights were determined after first blotting with a filter paper to
remove surface absorbed PBS. The water content was calculated by the following
equation:
Water content ¼ ½ðWs WdÞ=Ws (1)
Table 1. Formulation of p(HPMA/PEG-950-300)X1 and p(HPMA/PEG-300)X1-X3 hydrogels,






















p(HPMA/PEG-950)X1 5.55/0.80 6.5 1.036 579 ± 22 91.36 ± 2.21 75.4 ± 3.7
p(HPMA/PEG-475)X1 5.55/1.71 6.5 1.089 433 ± 24 79.64 ± 2.42 79.8 ± 2.5
p(HPMA/PEG-300)X1 5.55/2.63 6.5 1.103 171 ± 18 32.83 ± 1.14 84.0 ± 3.7
p(HPMA/PEG-300)X2 5.55/2.63 12.7 1.158 107 ± 06 19.81 ± 1.22 87.9 ± 2.6
p(HPMA/PEG-300)X3 5.55/2.63 19.2 1.176 77 ± 03 12.35 ± 0.17 89.2 ± 1.4
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where Wd and Ws are the weights of the samples in the dry and swollen states,
respectively. Each swelling experiment was repeated three times and the average value
was reported.
2.6. Determination of permeability of hydrogel formulations
All permeability tests were performed at 25 °C, using a diffusion cell which had two
cylindrical compartments (160 mL volume) and a connecting film holder (2.0 cm i.d.).
The donor compartment was filled with an aqueous doxorubicin solution in physiologi-
cal phosphate buffer solution (PBS; pH 7.4, 10 mM, 0.85% NaCl). The acceptor
compartment was filled with PBS, and stirred magnetically. Through the acceptor
chamber, the same buffer solution was pumped at a rate of 20 mL/h in a single-pass
manner and the effluent was collected by means of a fraction collector. The permeation
was continued for 24 h, and the collected samples were assayed spectrophotometrically
for doxorubicin at 490 nm. Each permeation experiment was repeated three times and
the permeability of doxorubicin (P) from various film formulations were calculated
using the following equation:
lnCt=C0 ¼ PSt=vh (2)
where P is the permeability of film (cm2/s); Ct and C0 are the concentration of
doxorubicin in the donor compartment at time t and t0, respectively; S is the film area
of the holder (cm2); t is time (s); v is the volume of donor compartment (mL), and h is
the film thickness (cm). Ct was calculated from the difference of C0, and the amount of
collected in the acceptor compartment. The slope of ln Ct/C0 vs. PS/vh yielded
permeability.
2.7. Contact angle studies
Contact angles to water, glycerol, and dimethyl sulfoxide of p(HPMA/PEG-950)X1,
p(HPMA/PEG-475)X1, p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2, and p(HPMA/
PEG-300)X3, formulations were measured by sessile drop method at 25 °C by using a
digital optical contact angle meter Phoneix 150 (Surface Electro Optics, Korea). The
sessile drop was formed by depositing the liquid from the above using a manual micro-
syringe on the membrane surfaces. Both the left and right contact angles and drop
dimension parameters were automatically calculated from the digitalized image. The
measurements were the average of five contact angles at least operated on three
membrane samples.
2.8. Interaction of major serum proteins with the hydrogel films
To determine the antifouling properties of the p(HPMA/PEG-950-300)X1, and p
(HPMA/PEG-300)X1-X3, formulations, the adsorption of human serum albumin
(HSA), human immuno-globulins (HIg), and fibrinogen was studied at 37 °C for 18 h
in a batch system. The initial concentration of each protein was 0.5 mg/mL in the indi-
vidual adsorption medium. The amount of adsorbed protein on the film surface was
obtained by the following equation:
q ¼ ½ðC0  CÞV =S (3)
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where q is the amount of protein adsorbed onto the film surface (μg/cm2); C0 and C are
the concentrations of protein in the solution before and after adsorption, respectively
(mg/mL); V is the volume of the protein solution; and S is the surface area of the film.
The amounts of protein adsorbed onto the five different p(HPMA/PEG-950-300)X1,
and p(HPMA/PEG-300)X1-X3 films, were determined using Coomassie Brilliant Blue
as described by Bradford [30]. Calibration curves were prepared from HSA, HIgs,
and fibrinogen and used in the calculation of the protein content of the solutions
(0.02–0.2 mg/mL).
2.9. In vitro cytotoxicity studies of hydrogel films
The lactate dehydrogenase (LDH) is a cytoplasmic enzyme. Normally, it is not secreted
outside the cells, but upon damage of cell membrane LDH leaks out. With LDH test, it
is possible to measure the release of LDH from cells based on a colorimetric quantita-
tion after an enzymatic reaction. This assay measures the LDH activity in the cell cul-
ture supernatants. LDH leakage was measured from cells by LDH Cytotoxicity
Detection Kit (Clontech®). Non-Radioactive Cytotoxicity assay was performed follow-
ing the manufacturer’s protocol. Human hepatocellular carcinoma (SNU398) cell line
was used to evaluate the cytotoxicity of the hydrogel formulations. The hydrogel for-
mulations (i.e. p(HPMA/PEG-950)X1, p(HPMA/PEG-475)X1, p(HPMA/PEG-300)X1,
p(HPMA/PEG-300)X2, and p(HPMA/PEG-300)X3), and their doxorubicin loaded
counterparts were placed in 96-well plates in triplicates. 2 × 104 SNU398 cells were
cultured on each well in 200 μL medium. LDH Cytotoxicity Detection Kit (Clontech®)
was used to measure the cytotoxicity and the effects of these formulations were calcu-
lated according to the manufacturer’s protocols. The readings were performed by using
an ELISA reader at the wavelength value of 490 nm. Each experiment was repeated at
least three times.
2.10. Antitumor activity of doxorubicin loaded hydrogel formulations
The five different p(HPMA/PEG-950-300)X1, and p(HPMA/PEG-300)X1-X3 hydrogel
formulations and their Doxorubicin loaded counterparts were placed in 24-well plates
in triplicates. 3 × 104 SNU398 cells were cultured on each well in 1.0 mL medium.
Control group with 3 × 104 cells cultured directly on bare plate surface without any
hydrogel was also included. The medium was changed at the third date and cell count-
ing was performed at the sixth date with a hemocytometer after trypsinization. For the
statistical analysis, Minitab® program was used. Fisher test was done with 95% confi-
dential interval value.
2.11. Determination of doxorubicin content of the hydrogel formulations
A sample was weighed (about 0.1 g) and was transferred in 10 mL of methanol. It was
incubated at 25 °C for 24 h to elute doxorubicin. The efficiency of the drug-loaded
hydrogel formulations was calculated by the following equation:
Loading efficiency ð%Þ ¼ ðAmount of drug in drug loaded hydrogel=
Total amount of drug used in the preparation of drug loaded hydrogelÞ
 100% ð4Þ
The drug concentration in the elution was measured as described above.
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2.12. Controlled release studies of doxorubicin from the hydrogel film formulations
The in vitro release studies were conducted in a continuous flow system with constant
stirring. Doxorubicin loaded five different hydrogel formulations (0.5 g), were placed in
the continuous flow drug release cell, and a physiological buffer solution (pH 7.4) was
introduced through the bottom inlet port of the flow cell at a flow rate of 10 mL/h at
37 °C with a peristaltic pump (model IPC, Ismatec, Düsseldorf, Germany). The effluent
was collected at predetermined time intervals, and the released doxorubicin (at a
maximum wavelength of 490 nm) was determined spectrophotometrically (model 1601,
Shimadzu). The analyzed solution was added back to the collected dissolution media to
maintain a constant volume. To study the effect of the doxorubicin loading on the
release rate, similar procedures were followed for 0.5 and 1.0 mg/mL drug-loaded sam-
ples. All experiments were repeated three times to minimize the error variation. There-
fore, the data presented in the graphs show the average values of three experiments.
The model drug concentration in the collected dissolution medium was calculated with
a calibration curve obtained from samples of known concentrations.
3. Results and discussions
3.1. Characterization of hydrogel films
The surface properties and swelling characteristics of hydrogels are critical in tissue
engineering applications, as it correlates with the diffusivity of oxygen, drugs, nutrients,
and other water-soluble metabolites. The swelling behaviors of the p(HPMA/PEG-950)
X1, p(HPMA/PEG-475)X1, p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2, and
p(HPMA/PEG-300)X3 hydrogels were investigated over a period of 24 h in PBS at
37 °C (Figure 2). The codes 300–950 and X1–X3 were assigned to various hydrogels
according to the difference in the PEG chains length and the amount of cross-linker
used, respectively. The dynamic swelling profiles of the hydrogel formulations exhib-
ited fast swelling behavior in the first hour and achieved the equilibrium state within
10 h in PBS. The initial faster swelling behavior of the copolymer hydrogels was due
to the osmotic pressure difference. On the other hand, the p(HPMA/PEG-950)X1,
p(HPMA/PEG-475)X1, and p(HPMA/PEG-300)X1 hydrogel formulations were used to
study the effect of chain length on the hydrogel properties and drug release behaviors.
Figure 2 shows the degree of swelling as a function of time for the hydrogel
formulations based on variable PEG chain length. The general trend for the tested for-
mulations is an increased swelling degree with increasing PEG chain length (Table 1).
Thus, the increase of PEG chain length in the HPMA/PEG hydrogel systems altered
the bulk properties of the resulting gels. The PEG chains of PEG–MEMA were
expected to be spread over the gel surface because the pendant PEG components were
more hydrophilic than the copolymer backbone, as evidenced by the swelling behavior
and contact angle data (Tables 1 and 2). The effect of the cross-linker content on the
swelling ratio for the p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2, and p(HPMA/
PEG-300)X3 hydrogel formulations in Table 1 indicates that the swelling ratios for
these gels increase in the order of p(HPMA/PEG-300)X1 > p(HPMA/PEG-300)X2 > p
(HPMA/PEG-300)X3. In these experiments, the cross-linker concentrations (i.e. Bis
AA) were 6.5, 12.7, and 19.2 μmoL. As the amount of cross-linker increases in the
hydrogel, the cross-linking density increases leading to the development of higher
elastic constraint when the gels are swelled in water (Table 1). This result implies that
the structure of the gels would become denser and more tightened as the amount of
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cross-linker increased and this would decrease the space between gel networks and
result in a decrease in the swelling ratio. Hence, higher the extent of BisAA in the gel,
swelling ratio becomes lower as expected. For the hyrogels containing the smallest
amount of cross-linker, 6.5 μmoL, the swelling percentage is about 171% at swelling
equilibrium. For the gel containing the highest amount of cross-linker, 19.2 μmoL, the
swelling percentage is about 77% at swelling equilibrium. In these hydrogel systems,
both of the monomers (i.e. HPMA and PEG–MEMA) were hydrophilic in nature and
thus permit large intake of water by the cross-linked gel network; even though the
cross-linker is less flexible and less hydrophilic.
The FTIR spectra of p(HPMA/PEG-300)X1 and its doxorubicin loaded counterpart had
the characteristic stretching vibration band of hydrogen-bonded alcohol (–OH) around
3430 cm−1, and the C=O stretching vibration of the ester group also appeared at 1719 cm−1
(Figure 3). On the other hand, several bands appeared in the fingerprint region for PEG
between 1600 and 1200 cm−1 on the p(HPMA/PEG-300)X1 structures. These peaks were
Figure 2. The swelling behavior: (A) p(HPMA/PEG-950)X1, p(HPMA/PEG-475)X1, and
p(HPMA/PEG-300)X1; (B) p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2, and p(HPMA/
PEG-300)X3, hydrogels in PBS at 37 °C. (Each swelling experiment was repeated three times,
and the p-value > 0.05 was used in the statistical analysis.)
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assigned to the –CH2 scissoring band of PEG at 1453 cm
−1 and the antisymmetric and sym-
metric stretching bands (–OCH2–CH2) of PEG at 1371 and 1248 cm
−1, respectively. The
spectra mark the presence of doxorubicin as evident from the observed bands at 1000–
1260 cm−1 (C–O stretching of alcohol) and 675–900 cm−1 (out of plane O–H bending).
Figure 4(A) and (B) shows scanning electron micrographs of the p(HPMA) and
p(HPMA/PEG-300)X1 hydrogels, respectively. The SEM micrograph of the p(HPMA)
hydrogel surface showed a porous structure (Figure 4(A)). For the surface of p(HPMA/
PEG-300)X1 hydrogel networks, PEG chains were incorporated with the co-monomer
PEG–MEMA, exhibited a non-porous and smooth structure compared to the surface of
p(HPMA) (Figure 4(B)). A detailed examination of the SEM figure showed that the
pores had a view of either filled or closed with PEG chains and had a much smoother
surface structure compared to p(HPMA) hydrogel surfaces.
3.2. Contact angle data of hydrogel films
The PEG brushes is of significant importance as the peculiar physicochemical properties
of PEG afford surfaces with interesting non-biofouling properties such as resistance to
protein adsorption or cells adhesion are obtained. These parameters are critically impor-
tant for the development of biomaterials in the field of tissue engineering and regenera-
tive medicine. Therefore, contact angle measurements are used in the characterization of
material surfaces to describe the hydrophilicity. The wettability of biomaterial surfaces
can be examined by comparing the contact angles for water and diiodomethane; since
these two solvents are often used as reference liquids in analyses of interaction of polar
and apolar solvents with solid surfaces. The results of the contact angle measurements
of water, glycerol, and dimethyl sulfoxide on the p(HPMA), p(HPMA/PEG-950)X1,
p(HPMA/PEG-475)X1, p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2, and p(HPMA/
PEG-300)X3, hydrogels surfaces are presented in Table 2. It can be seen that all the
composite hydrogels (i.e. PEG carrying hydrogels) showed lower water contact angles
than those of the pure p(HPMA). All the investigated samples yielded a different contact
angle value, and all the tested hydrogel compositions had polar surfaces. As seen in
Table 2, as the PEG chains length increased in the macro-monomer structure, the water
contact angles decreased. It should also be noted that, the molar ratio of the
macro-monomer with larger PEG chains was lower than that of the macro-monomer
with smaller PEG chains (Table 2), since the PEG carrying macro-monomer ratio was
maintained at 50% in each hydrogel formulation. This suggests that the hydrogel
containing the macro-monomer with high PEG chain length should have the highest
surface density because it contains the lowest methylether methacrylate (MEMA) units
of the heterofunctional polymer backbone chains. Thus, the contact angle value of the
Table 2. Contact angle values of the p(HPMA), p(HPMA/PEG-950-300)X1, and
p(HPMA/PEG-300)X1-X3 hydrogel formulations using water, glycerol, and dimethyl sulfoxide.
Water Glycerol Dimethyl sulfoxide
p(HPMA) 70.1 ± 3.8 72.3 ± 3.1 35.7 ± 1.4
p(HPMA/PEG-950)X1 43.4 ± 0.9 49.8 ± 1.7 36.1 ± 1.4
p(HPMA/PEG-475)X1 50.2 ± 1.3 55.7 ± 2.4 33.6 ± 0.8
p(HPMA/PEG-300)X1 57.8 ± 1.2 62.7 ± 1.9 32.7 ± 1.1
p(HPMA/PEG-300)X2 54.7 ± 2.4 58.2 ± 2.1 28.3 ± 0.6
p(HPMA/PEG-300)X3 48.9 ± 1.6 51.5 ± 2.2 24.7 ± 0.9
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hydrogels decreased with increasing PEG chain length in the macro-monomer structure,
as indicated by an increase in the swelling ratio of the copolymer hydrogel. On the other
hand, the relatively high contact angles was observed with the hydrogels containing
Figure 3. The FTIR spectra of p(HPMA/PEG-300)X1 and its doxorubicin loaded counterpart.
Figure 4. Scanning electron micrographs of (A) the p(HPMA) and (B) p(HPMA/PEG-300)X1
hydrogels.
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lower molecular weight PEG–MEMA macro-monomer can be due to an incomplete
coverage of the uppermost surface by PEG chains. This data highlights the importance
of the incorporation of PEG–MEMA macro-monomer with varying PEG chain length in
the co-monomer structure. A similar trend of reduced contact angle values with
increasing PEG molecular weight was also observed in other studies.[31–33]
3.3. Effect of hydrogel composition on the permeability
Permeation studies were carried out in vertical type chambers with a volume of 160
mL in the donor and acceptor chamber and a permeation area of 3.14 cm2. All perme-
ability experiments were carried out by using physiological buffer solution (pH 7.4,
10 mM, 0.85% NaCl) at 25 °C. The relationship between the PEG chains length and
cross-linker density on the permeability of hydrogel formulation values was studied by
varying the PEG chains length of macro-monomer and BissAA concentration in the
polymerization mixture (Table 1). It was observed that the permeability to doxorubicin
was substantially increased when the PEG chains length was increased in the hydrogel
formulations (Table 1). The increment in the permeability values of the hydrogels can
be attributed to the higher hydrophilicity of the PEG and the greater availability of
PEG molecules in the structure of polymer as the chains length increases. As seen in
Table 1, the p(HPMA/PEG-950)X1 formulation had the highest PEG chains length
which had a substantially higher water content and a higher permeability to doxorubicin
(91.36 cm2s−1). The location of the PEG had a substantial effect on the swelling and
also permeability. When the PEG chains length increased in the hydrogel films, the
permeability to doxorubicin increased. PEG chains remained in the bulk gel product,
due to its high content of polar functional groups and large size. Additionally, the
increase in the PEG chains length of macro-monomer resulted in the formation of loose
networks, and the absorption of large quantities of water. This makes the hydrogel films
more permeable to doxorubicin.
In order to study the influence of the cross-linking density on the doxorubicin
permeability of hydrogels, formulations were prepared by changing the molar content
of the cross-linking agent BisAA. Table 1 shows the permeability data of hydrogel
formulations with three different cross-linker densities. It is clear that doxorubicin per-
meability was significantly hindered as the hydrogel cross-linking density was
increased. An increase in the molar concentration of the cross-linking agent BisAA
decreased the molecular weight polymer chains between cross-links, which in turn
resulted in a smaller network mesh size. Doxorubicin permeability from hydrogel
containing 19.2 μmole of BisAA was more obstructed and consequently slower than
that of the hydrogel synthesized with 6.5 μmole of BisAA (Table 1). Hence, the
increasing chains length of PEG in the hydrogel networks resulted in an increase in the
drug permeability, whereas the declined effect of cross-linker was significantly higher
when the amount of BisAA increased due to the decrease mesh size of the polymer
networks.
3.4. Protein adsorption studies
One of the objectives in this study was to investigate the effects of the variations in
PEG chain length and cross-linker density on surface properties of the hydrogel films.
Biochemical insight into the behavior of tethered PEG under biological conditions was
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gained through assays on protein adsorption and cellular attachment experiments to a
hydrophilic PEG layer. For these purposes, p(HPMA/PEG–MEMA)-X1 with different
lengths of PEG and with different ratios of cross-linker density were synthesized
(Table 1). The biomolecules interaction properties of p(HPMA/PEG-950-300)X1, and p
(HPMA/PEG-300)-X1-X3, were tested with three important plasma proteins (i.e. serum
albumin, fibrinogen, and immunoglobulins) in a batch-wise manner. Single protein
solutions of HSA albumin (67 kD), fibrinogen (340 kD), and Igs (150–170 kD) in
physiological buffer solution (pH 7.4) at a concentration of 0.5 mg/mL were then
exposed to the six different surfaces for a period of 12 h at 37 °C, using a previously
described procedure.[34] The tested proteins reached their maximum adsorption values
on hydrogel formulations in about 8.0 h and remained constant after this period. The
amounts of adsorbed HSA, fibrinogen, and Igs on the hydrogel surface are presented in
Table 3. The isoelectric points of the albumin, fibrinogen, and Igs were 4.0, 6.0, and
6.2, respectively, and therefore, these proteins carried negative charges at a blood pH
of 7.4. It should be noted that all PEG-modified surfaces showed significant decrease
in HSA, fibrinogen, and immunoglobulins adsorption compared to the control surface
(i.e. p(HPMA)). The relatively high basic component of the PEG-carrying hydrogel
films could create a repulsive force against the negatively charged blood proteins. For
example, the adsorption of all the tested proteins was significantly increased when the
PEG MW was reduced from 950 to 300 (Table 3). Protein adsorption was lowest on
the surfaces with the highest PEG chains surface density. Thus, p(HPMA/PEG-950)X1
surface reduced protein adsorption from 1.14 to 0.46 μg/cm2 for HSA, from 1.89 to
0.53 μg/cm2 for fibrinogen, and 1.36 to 0.67 μg/cm2 for Igs at 0.5 mg/mL individual
tested protein concentration. The amounts of adsorbed HSA were significantly lower on
all the tested hydrogels surfaces compared to fibrinogen and Igs. Adsorption of these
proteins on the hydrogel formulations was found to be further increased by increasing
the cross-linker ratio in the hydrogel structure. The highest proteins adsorption was
found on p(HPMA/PEG-300)-X3 surface. Thus, an increase in the chains length of
PEG–MEMA macro-monomer was found to improve the antifouling properties of the
materials. On the other hand, as shown in Table 3, the amounts of albumin, fibrinogen,
and Igs adsorbed onto hydrogels were increased as the cross-linking density increased.
The reduction in the adsorbed protein amounts can be mainly due to the reduction of
water content on the surface of the hydrogels. In this work, the hydrophilic PEG chains
should have been moved from the interior to the surface of the materials because the
material bulk should have been less hydrophilic than that of the aqueous surroundings,
so all PEG introduced into the films showed good antifouling surface properties. These
results were in good agreement with the previous related literature.[35–37]
Table 3. HSA, fibrinogen, and Igs adsorption on control p(HPMA), p(HPMA/PEG-950-300)X1,
and p(HPMA/PEG-300)X1-X3 hydrogel formulations, from PBS (pH 7.4) buffer.
HSA (μg/cm2) Fibrinogen (μg/cm2) Immunoglobulins (μg/cm2)
P(HPMA) 9.35 ± 0.38 11.87 ± 0.76 7.33 ± 0.33
p(HPMA/PEG-950)X1 0.46 ± 0.04 0.53 ± 0.06 0.67 ± 0.03
p(HPMA/PEG-475)X1 0.96 ± 0.07 1.24 ± 0.21 1.08 ± 0.02
p(HPMA/PEG-300)X1 1.14 ± 0.08 1.89 ± 0.06 1.36 ± 0.03
p(HPMA/PEG-300)X2 1.87 ± 0.07 2.63 ± 0.14 1.88 ± 0.05
p(HPMA/PEG-300)X3 2.54 ± 0.31 3.25 ± 0.17 2.56 ± 0.23
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3.5. In vitro doxorubicin-release studies
3.5.1. Effect of PEG chains length
Hydrogels have been extensively investigated as controlled drug release systems due to
their excellent physicochemical properties. Drug release from hydrogel matrices is
affected by many factors, such as their swelling properties, network porosity, and the
erosion of the hydrogel matrix, as well as drug–polymer interactions.[38–40] In the pre-
sented hydrogel systems, the amino groups of doxorubicin are positively charged at pH
7.4, because the pKa value of the primary amine in the sugar moiety of doxorubicin is
8.25, and the Lewis acid groups (γ−) of the PEG molecules have partially negative
charge. Thus, polymer and drug can interact electrostatically at pH 7.4. The results for
the doxorubicin loading efficiency of the hydrogel formulation are presented in Table 1.
The entrapment efficiency (%) of a drug depended on the type of matrix material,
entrapment method of the drug, and the polymer networks preparation conditions. As
seen in this table, the drug-loading efficiency of the hydrogel film formulations
depended on the PEG chain length and cross-linker density of the formulations. The
entrapment efficiency decreased from 84 to 75% when the PEG chain length in the
macro-monomer was increased from 300 to 975Mn. Additionally, as the cross-linker
density increased, the doxorubicin loading efficiency in the hydrogel formulation
increased. The effect of the PEG chains length of the macro-monomer on the doxorubi-
cin release kinetics for the p(HPMA/PEG-950-300)X1, formulations are presented in
Figure 5. The release profiles indicate that the amount of doxorubicin released
increased when the PEG chain length of the hydrogel increased. The p(HPMA/PEG-
300)X1 hydrogel films showed 60.3% release, whereas the p(HPMA/PEG-475)X1 and
p(HPMA/PEG-950)X1 hydrogel films showed 85.4 and 98.3% release, respectively, at
37 °C and 480 min with 1.0 mg/mL doxorubicin loading (Figure 5(B)). These results
can be explained by the more hydrophilic nature of the p(HPMA/PEG-950)X1 hydrogel
formulations (Table 1). With the chains length of the macro-monomer (i.e. PEG–
MEMA) increasing in the copolymer network, cumulative release from the formulation
was increased. This observation was also expected because more hydrophilic PEG in
the copolymer structures resulted in faster movement of the water to the surface of the
drug-loaded film.[39,40] Additionally, the cumulative release of doxorubicin increased
from 42.1, 54.1, and 61.3 to 60.2, 85.4, and 98.2% for p(HPMA/PEG-300)X1
p(HPMA/PEG-475)X1 and p(HPMA/PEG-950)X1 hydrogel formulations, respectively,
with increasing initial drug content of the formulations from 0.5 to 1.0 mg/mL in the
polymerization medium. This can be explained by inclusion complex formation
between doxorubicin and polymer networks during loading process, and these internal
interactions at high polymer ratio may provide a force to prevent the drug molecules
from releasing and resulted in low percent cumulative release.[41,42] This could not be
a case for the high drug-loaded formulations where the cumulative releases were higher
about 18–37% compared to low drug-loaded counterparts in the time frame of the
experiment. At high loading, only a small portion of the drug could be interacted with
the polymer network, and remaining drug could be freely suspended in the vicinity of
the polymer networks. Thus, the high drug-loaded formulations showed high percent
cumulative releases compared with the low drug-loaded counterparts.
3.5.2. Effect of cross-linker density on release of doxorubicin
The release profiles of doxorubicin in p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2,
and p(HPMA/PEG-300)X3 hydrogel formulations, cross-linked with different ratios of
Journal of Biomaterials Science, Polymer Edition 669
BisAA, are shown in Figure 6. It showed that the release rate of doxorubicin for the
p(HPMA/PEG-300)X1 hydrogel formulation was higher and faster than those for
the p(HPMA/PEG-300)X2 and p(HPMA/PEG-300)X3 formulations. This was due to
the lower cross-linking density and higher swelling ratio of p(HPMA/PEG-300)X1.
From this and above observations, the doxorubicin release behavior mainly depended
on the swelling ratio of the hydrogel formulations. Figure 6 also presents cumulative
doxorubicin release profiles for the hydrogel formulations. The p(HPMA/PEG-300)X1
hydrogel films showed 60.3% release, whereas the p(HPMA/PEG-300)X2 and
p(HPMA/PEG-300)X3 hydrogel films showed 53.2 and 43.1% release, respectively, at
37 °C and 480 min with 1.0 mg/mL doxorubicin loading. The initial release rate of the
drug from the hydrogels was rapid, and this initial fast release may be attributed to the
rapid diffusion of doxorubicin that was loaded close to the surface of the hydrogels.
Later on, the drug was released more slowly from the hydrogels.
Figure 5. The effect of the PEG chains length of the macro-monomer on the doxorubicin
release kinetics for the p(HPMA/PEG-300)X1, p(HPMA/PEG-475)X1, and p(HPMA/PEG-950)
X1: (A) at 0.5 mg/mL, and (B) at 1.0 mg/mL drug loading. (The data presented in the graphs
show the average values of three experiments, and the p-value > 0.05 was used in the
statistical analysis.)
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3.5.3. Kinetic evaluation of drug release mechanism
The mathematical theory of diffusion for isotropic substances is based on the
hypothesis that the rate of transfer of the diffusing substance through a unit of area of
a section is proportional to the concentration gradient measured normal to the section
(i.e. Fick’s first law of diffusion). Fick’s first law assumes that the concentration gradi-
ent is independent of time. However, during a real diffusion process, the concentration
of the diffusing species within the host matrix is changing with the time at any given
position.[43] The Fickian mechanism is often applied to diffusion-controlled release
behavior because of its simple mathematics. A situation that does not conform to these
conditions is described as either case II or anomalous behavior.[44]
To analyze the in vitro release data, various kinetic models were used to describe
the release kinetics. The following plots were used to analyze release behaviors;
(i) cumulative % drug release vs. time (zero-order kinetic model, Equation (5)); (ii) log
cumulative of % drug remaining vs. time (first-order kinetic model, Equation (6)); (iii)
cumulative % drug release vs. square root of time (Higuchi model, Equation (7)); (iv)
log cumulative % drug release vs. log time (Korsmeyer–Peppas model, Equation (8)),
and (v) cube root of drug % remaining in matrix vs. time (Hixson-Crowell cube root
law, Equation (9)).
Figure 6. The effect of the cross-linker density on the doxorubicin release kinetics for the
p(HPMA/PEG-300)X1, p(HPMA/PEG-300)X2, and p(HPMA/PEG-300)X3; (A) at 0.5 mg/mL,
and (B) at 1.0 mg/mL drug loading. (The data presented in the graphs show the average values
of three experiments, and the p-value > 0.05 was used in the statistical analysis.)
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Mt ¼ M1k0t (5)
Mt ¼ M1ekt (6)
Mt ¼ M1kH t1=2 (7)
Mt ¼ M1KKPtn (8)
ðMt M1Þ1=3 ¼ kHCt (9)
where Mt and M∞ are the respective mass of drug release at time t and infinite
(equilibrium) time, respectively. n is the diffusion exponent and related to drug release
kinetics. ko, k1, kH, KKP, and kHC are kinetic constants, t is the release time, and n is
the diffusional exponent that can be related to the drug transport mechanism. For a thin
hydrogel film, when n = 0.5, the drug release mechanism is Fickian diffusion. When
n = 1, Case II transport occurs, leading to zero-order release. When the value of n is
between 0.5 and 1.0, anomalous transport is observed.[43,44] The mathematical theory
of diffusion in isotropic substances is based on the hypothesis that the rate of transfer
of the diffusing substance through a unit area of a section is proportional to the concen-
tration gradient measured normal to the section, that is, Fick’s first law of diffusion.
Information about the release mechanism can be gained by fitting the drug release data
and comparing the value of n to the semi-empirical value of various geometry’s
reported by Peppas (11). The early-time (Equation (10)) and late-time (Equation (11))
approximation release equations are approximations of the equation that one obtains
when solving Fick’s second law of diffusion under initial and boundary conditions
equivalent to those of testing in this work [44]:
Mt=M1 ¼ 4ðDEt=pd2Þ0:5 (10)
Mt=M1 ¼ 1 ð8=p2Þ expðp2DLt=d2Þ0:5 (11)
where Mt/M∞ is the fractional drug release, t is the release time, DE and DL are the
corresponding diffusional coefficients, and δ is the diffusional distance (film thick-
ness). Evaluation of doxorubicin release kinetics from hydrogels was performed by
calculating the diffusion coefficients (DE and DL) using the early-time and late-time
approximation release equations. A plot of Mt/M∞ vs. t
0.5/δ is initially linear and from
the slope of early-time approximation equation DE can be evaluated. A plot of log
[(π2 /8) (1 − Mt/M∞)] vs. t is linear and from the slope of late-time approximation
equation DL can be evaluated.
The diffusion coefficients, DE and DL of doxorubicin from the hydrogels were ana-
lyzed using Equations (10) and (11) and the results are given in Table 4. The goodness
of fit in different release kinetic models (zero-order, first-order, Higuchi, Hixon-Crowell
and Korsmeyer–Peppas ‘power-law’) was evaluated to understand the mechanism of
drug release (Tables 5 and 6). The zero- and first-order release mechanisms could not
be found to be valid for p(HPMA/PEG-950-300)X1, and p(HPMA/PEG-300)-X1-X3,
hydrogel formulations with a drug loading 1.0 mg/mL (Table 5). The high values of the
coefficient of linear regression (R2 > 0.95) for the Higuchi, Hixon-Crowell, and Kors-
meyer–Peppas models confirmed that these analysis are valid for hydrogel films with
two different drug loading concentrations (Table 6). The correlation coefficients for the
Hixon-Crowell and Korsmeyer–Peppas models were higher than those for the Higuchi
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model for all the hydrogel films. The doxorubicin release mechanisms from hydrogel
films of p(HPMA/PEG-300)X1-X3, and p(HPMA/PEG-950-300)X1, were evaluated,
and the n values were observed to be between 0.53 and 0.86 (Table 6). Thus, the
in vitro release mechanism in the hydrogel film formulations could therefore be
described by anomalous transport mechanism. In addition, the n values related to drug
release kinetics were in all cases lower than 1 in all cases, and this indicated that drug
release was not time-dependent and controlled by the relaxation process due to the
swelling of the polymeric network. The values of model release parameters n and KKP
(rate constant) are inversely related. A higher value of KKP may suggest burst drug
release from the polymeric hydrogel networks. The DE values of doxorubicin from the
hydrogel films with different PEG chains length were analyzed with Equation (10) and
the results are given in Table 4. The DE values of the hydrogel films of p(HPMA/PEG-
950-300)X1, were found to be 8.7 × 10−7, 12.8 × 10−7, and 18.5 × 10−7 cm2/s, respec-
tively. The same trend was observed for the DL values (Table 4). As observed in the
table, the DE and DL values decreased as the chains length of PEG increased in the
hydrogel formulations. Figures 5 and 6 show the effect of the drug loading on the
release pattern as a function of time for hydrogel films of p(HPMA/PEG-950-300)X1,
and p(HPMA/PEG-300)-X1-X3. In all the samples, at any given time, the drug release
increased with an increase in the percent loading of the doxorubicin in the hydrogel
films at pH 7.4 and at 37 °C. As shown in Figure 5, the release of doxorubicin from
each hydrogel formulation was nearly linear in the first 2.0 h, and this suggested an
almost constant rate of doxorubicin release during this period. The hydrogel formula-
tions had similar release profiles, despite different doxorubicin contents. This indicates
that at a lower drug concentration, most of the drug molecules remained bound to the
polymeric chains of the hydrogels, whereas at a higher drug concentration, the percent-
age of unbound drug molecules increased in the polymer networks. The maximum
doxorubicin release for the p(HPMA/PEG-950)X1 hydrogel formulation with different
drug amounts loaded (0.5 and 1.0 mg/mL) was determined to be 61.3 and 98.3% after
480 min, respectively. Doxorubicin is freely soluble in a physiological phosphate buffer
(pH 7.4); as a result, the rate of depletion of the drug in the polymer at a high
concentration was faster than at a low concentration. In this process, the hydrogel
became more permeable at a high drug concentration, and this increased the diffusion
constant of the drug in the polymer network.[30,31] In Table 4, the diffusion
constant of the drug was observed to be much lower for 1.0 mg/mL drug-loaded
p(HPMA/PEG-950)X1 films than for the other hydrogel formulations.
Table 4. Doxorubicin diffusion coefficients calculated with the early-time and late-time
approximation release equations and for the different molecular weight of PEG and cross-linked
ratio carrying p(HPMA/PEG–MEMA) hydrogel formulations.
Formulation DE (cm
2 s−1) × 107 R2 DL (cm
2 s−1) × 107 R2
p(HPMA/PEG-950)X1 8.70 0.868 14.7 0.975
p(HPMA/PEG-475)X1 12.8 0.906 15.9 0.985
p(HPMA/PEG-300)X1 18.5 0.957 18.3 0.999
p(HPMA/PEG-300)X2 21.0 0.959 19.4 0.998
p(HPMA/PEG-300)X3 22.5 0.972 20.9 0.976
Journal of Biomaterials Science, Polymer Edition 673
3.6. Cytotoxicity studies using LDH release test.
Lactate dehydrogenase (LDH) test was performed to determine the cytotoxicity of the
hydrogel formulations. SNU398 cells were seeded in 96-wells plates as reported for the
LDH assay. Percentage of cell viability was calculated by comparison to 0% viability
(positive control) and 100% viability of untreated cells. All experiments were per-
formed in triplicate. As shown in Figure 7, all hydrogel formulations showed low cyto-
toxicity to SNU398 cells, and the relative cell toxicity of the hydrogels was lower than
7%. Altogether, no clear difference between hydrogel formulations was observed with
regard to cytotoxicity. Variability of the cytotoxicity values was the smallest with the
hydrogel formulation except that p(HPMA-PEG-950)-X1 formulation had no cytotoxic
effect on the SNU398 cells. The lower cytotoxicity of hydrogels should be attributed to
the presence of large quantity of water in the network. The low cytotoxicity to
SNU398 cell line suggested that these hydrogel formulations could be used as excellent
drug carrier material for the future biomedical application.
3.7. In vitro antitumor activity
Hydrogels are cross-linked hydrophilic polymer. They are an important class of
biomaterials, and have been used in several biotechnological and biomedical applica-
tions.[6, 10–20] In this study, we prepared a series of hydrogel with different PEG chains
length and cross-linking density to be used as implant drug release system. Doxorubicin,
one of most widely used anticancer drug was selected as the model drug-loaded inside
these hydrogel formulations, to investigate the drug release rates and in vitro cytotoxicity
Table 5. Zero- and first-order Doxorubicin release kinetic of the different molecular weight of
PEG and cross-linked ratio carrying p(HPMA/PEG–MEMA) hydrogel formulations.
Formulation
Zero order First order
k0 × 10
3 (min−1) R2 k × 103 (min) R2
p(HPMA/PEG-950)X1 1.19 0.733 2.07 0.618
p(HPMA/PEG-475)X1 1.50 0.791 2.89 0.673
p(HPMA/PEG-300)X1 1.86 0.864 4.31 0.713
p(HPMA/PEG-300)X2 1.99 0.876 5.24 0.724
p(HPMA/PEG-300)X3 2.11 0.904 5.72 0.749
Table 6. Higucci, Hixson-Crowell, and Korsmeyer–Peppas Doxorubicin release parameters for













p(HPMA/PEG-950)X1 3.50 0.860 0.71 0.968 1.40 0.53 0.974
p(HPMA/PEG-475)X1 4.29 0.906 0.75 0.976 7.22 0.57 0.980
p(HPMA/PEG-300)X1 5.12 0.953 0.76 0.988 2.24 0.67 0.978
p(HPMA/PEG-300)X2 5.45 0.958 0.72 0.986 1.04 0.81 0.969
p(HPMA/PEG-300)X3 5.64 0.972 0.73 0.999 0.75 0.86 0.985
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on SNU398 cells. The cytotoxicity test was used to evaluate in vitro antitumor activity of
doxorubicin loaded hydrogel formulations using doxorubicin free hydrogel counterpart































































Figure 7. Cytotoxicity to SNU398 cells, and the relative cell toxicity of the all hydrogel
formulations. (The data presented in the graphs show the average values of the at least three
experiments, and the p-value > 0.05 was used in the statistical analysis.)
Notes: H1: p(HPMA/PEG-950)X1 hydrogel; H2: p(HPMA/PEG-475)X1; H3: p(HPMA/PEG-300)
X1; H4: p(HPMA/PEG-300)X2; H5: p(HPMA/PEG-300)X3; D1: 0.5 mg /mL doxorubicin loaded;















Figure 8. The variation of cell viability against two different drug concentrations. (The data
presented in the graphs show the average values of the at least three experiments, and the
p-value > 0.05 was used in the statistical analysis.)
Notes: H1: p(HPMA/PEG-950)X1 hydrogel; H2: p(HPMA/PEG-475)X1; H3: p(HPMA/PEG-300)
X1; H4: p(HPMA/PEG-300)X2; H5: p(HPMA/PEG-300)X3.
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PEG-475)X1-D, p(HPMA/PEG-300)X1-D, p(HPMA/PEG-300)X2-D, or p(HPMA/PEG-
300)X3-D were performed against human hepatocellular carcinoma (SNU398) cells. The
variations of cell viability against two different drug concentrations were shown in
Figure 8. The cell viabilities of the doxorubicin free hydrogel formulations for SNU398
cells were all above 80%, which clearly indicated that the blank hydrogel has no apparent
cytotoxicity on SNU398 cells, showing the good biocompatibility of these hydrogel for-
mulations. To evaluate and compare the in vitro cytotoxicity of the drug-loaded hydrogel
formulation, the hydrogel formulations with two different concentrations of drug loading
(i.e. 0.5 and 1.0 mg/g hydrogel) were used to determine the cell viability during six days
incubation periods. After six days incubation period, the cell viabilities were less than
0.02% for all doxorubicin-loaded hydrogels. Doxorubicin released from the hydrogels
with two different concentrations of drug loading have biological activities and show
high cytotoxicity to the SNU398 cells. With the increase in initial drug concentration, the
cytotoxicity of the drug-loaded hydrogel enhances.
4. Conclusions
Biocompatibility property makes hydrogels a useful delivery platform for the develop-
ment of localized chemotherapy. Modifying the properties of hydrogels by changing
PEG chains length and cross-linking density provided control over doxorubicin release
rates. This study demonstrated that p(HPMA/PEG–MEMA)-based hydrogel formula-
tions can serve as valuable local delivery platform for cancer research and therapy. The
in vitro cytotoxicity of the hydrogels was demonstrated to be low since LDH leakage
from the cells was less than 7% for all the tested hydrogel formulations.
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